Online inquiry

IVTScrip™ mRNA-Human ANXA7, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK19765MR)

This product GTTS-WK19765MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ANXA7 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001156.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 310
UniProt ID P20073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ANXA7, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK19765MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18848MR IVTScrip™ mRNA-Human ANP, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANP
GTTS-WK8602MR IVTScrip™ mRNA-Human ADAMTS2, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADAMTS2
GTTS-WK3776MR IVTScrip™ mRNA-Human FZ4, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FZ4
GTTS-WK21268MR IVTScrip™ mRNA-Human AOAH, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AOAH
GTTS-WK20307MR IVTScrip™ mRNA-Human ANKRD20A12P, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANKRD20A12P
GTTS-WK23221MR IVTScrip™ mRNA-Human ARHGEF6, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF6
GTTS-WK8988MR IVTScrip™ mRNA-Human AGAP2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGAP2
GTTS-WK14388MR IVTScrip™ mRNA-Human AGAP2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGAP2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW